Key Highlights

  • Shares closed up 7.96% at $36.90, snapping an eight-day losing streak.
  • JPMorgan initiated coverage at Overweight with an $84 price target, implying roughly 145% upside from the prior close.
  • The firm cited strong Phase 3 data for the company's oral lysergide formulation and noted an FDA submission targeted for the first half of 2027.
  • Analyst sentiment was already broadly bullish, with a consensus Buy rating and an average target near $66.
  • The stock remains below its 50-day average of about $40.

JPMorgan Initiation Highlights Strong Phase 3 Data

Definium Therapeutics (NASDAQ:DFTX), formerly known as Mind Medicine, shares advanced after JPMorgan initiated coverage on the stock with an Overweight rating and an $84 price target, implying roughly 145% upside from the prior close. Definium Therapeutics is a late-stage clinical biopharmaceutical company applying scientific rigor to psychedelic and psychoplastogenic science to develop treatments for psychiatric and neurological disorders.

The firm's call centered on the company's lead candidate, an oral lysergide formulation that has received FDA Breakthrough Therapy Designation and is being evaluated in Phase 3 trials for generalized anxiety disorder and major depressive disorder, citing strong clinical data and an FDA submission targeted for the first half of 2027.

Shares Snap an Eight-Day Losing Streak

Today's gain snapped an eight-day losing streak for the stock, which had been trading below its 50-day average of roughly $40 heading into the JPMorgan initiation. The new coverage adds to an already broadly bullish analyst picture, with consensus on the stock at Buy and an average price target near $66.

Move Comes as Healthcare Outperforms a Cautious Biotech Group

The advance came as healthcare broadly outperformed, with the sector ETF up about 1.6%, even as the wider biotech group pulled back amid higher interest rates and broader market uncertainty. That divergence underscores how much of today's move was driven by the company-specific JPMorgan initiation rather than sector-wide tailwinds.

What Comes Next for the Lysergide Program

Investors are likely to watch for further Phase 3 trial updates ahead of the targeted first-half-2027 FDA submission, along with any additional analyst coverage following JPMorgan's bullish initiation, as the next catalysts for the stock.